Skip to main content

Table 1 Chronical list of epigenetic drugs approved for cancer by the FDA and other authorities

From: Epigenetic modulation of antitumor immunity for improved cancer immunotherapy

Name Year of approval Mechanisms of action Clinical applications
Azacitabine 2004 DNMT inhibitor AML; CMML; MDS
Decitabine 2006 DNMT inhibitor AML; CMML; MDS
Vorinostat 2006 HDAC inhibitor Cutaneous manifestations of cutaneous T-cell lymphoma (CTCL)
Romidepsin 2009 HDAC inhibitor CTCL  and peripheral T-cell lymphoma (PTCL)
Belinostat 2014 HDAC inhibitor Relapsed or refractory PTCL
Panobinostat 2015 HDAC inhibitor Multiple myeloma
Chidamidea 2015 HDAC inhibitor Relapsed/refractory PTCL
Enasidenib 2017 IDH2 inhibitor Relapsed or refractory AML
Ivosidenib 2018 IDH1 inhibitor Relapsed or refractory AML
Tazemetostat 2020 EZH2 inhibitor Epithelioid sarcoma and relapsed or refractory follicular lymphoma
  1. aChina FDA’s approval